Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Stem Cells. 2020 Oct 1;38(10):1206-1215. doi: 10.1002/stem.3239. Epub 2020 Jun 7.
Retinal diseases constitute a genetically and phenotypically diverse group of clinical conditions leading to vision impairment or blindness with limited treatment options. Advances in reprogramming of somatic cells to induced pluripotent stem cells and generation of three-dimensional organoids resembling the native retina offer promising tools to interrogate disease mechanisms and evaluate potential therapies for currently incurable retinal neurodegeneration. Next-generation sequencing, single-cell analysis, advanced electrophysiology, and high-throughput screening approaches are expected to greatly expand the utility of stem cell-derived retinal cells and organoids for developing personalized treatments. In this review, we discuss the current status and future potential of combining retinal organoids as human models with recent technologies to advance the development of gene, cell, and drug therapies for retinopathies.
视网膜疾病是一组具有遗传和表型多样性的临床病症,可导致视力损害或失明,目前治疗选择有限。体细胞重编程为诱导多能干细胞和生成类似于天然视网膜的三维类器官的技术进步为研究疾病机制和评估目前无法治愈的视网膜神经退行性变的潜在治疗方法提供了有前途的工具。下一代测序、单细胞分析、先进的电生理学和高通量筛选方法有望极大地提高基于干细胞的视网膜细胞和类器官在开发个性化治疗中的应用。在这篇综述中,我们讨论了将视网膜类器官作为人类模型与最近的技术相结合的现状和未来潜力,以推进基因、细胞和药物治疗视网膜疾病的发展。